Ultrasound to Facilitate Stone Passage
University of Washington · with Indiana University, VA Puget Sound Health Care System · NCT04796792
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18+ · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 140
- US sites recruiting
- 2
- Study start
- April 1, 2023
- Record last updated
- December 9, 2025
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
This is a prospective, open-label, multi-center study to test the clinical feasibility of facilitating stone passage by the combination of breaking and repositioning stones with ultrasound, without the need for anesthesia.
Being studied: Burst Wave Lithotripsy (BWL) and Ultrasonic Propulsion (UP)
Conditions: Urinary Stone; Urinary Calculi
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
- Individuals presenting with at least one kidney stone
- Stone with maximum dimension > 2 mm and ≤ 7 mm as determined by clinical imaging
- Individuals with SCI - (Phase 2b only)
Exclusion Criteria
- Individuals under 18 years of age
- Individuals who are pregnant or who are trying to get pregnant
- Prisoners
- with cognitive impairment that would limit their ability to comprehend their role in consent or participation.
- Individuals who are unable to read or understand English
- Individuals who are unable or unwilling to participate in follow up activities
- Individuals who cannot be positioned for ultrasound imaging
- Individuals with uncorrected bleeding disorders or coagulopathies
- Individuals receiving anticoagulants and who are unable or not willing to temporarily cease the medication for the investigational procedure
- Individuals with a calcified abdominal aortic aneurysm or calcified renal artery aneurysm ipsilateral to the renal stone targeted by the investigational procedure
- Individuals with a solitary kidney
- Individuals with an uncorrected urinary tract obstruction
- Individuals with an untreated infection
- Individuals with a comorbidity risk which, at the discretion of the physician, would make the patient a poor candidate for the investigational procedure
- Individuals who have received two previous investigational procedures for the same stone target
- Individuals who have undergone the investigational procedure within the last 21 days or still have unresolved AEs from a previous investigational procedure.
Recruiting US locations
VA Puget Sound Health Care System
Seattle, WA 98108
Site contact: Branda Levchak · branda.levchak@va.gov
University of Washington
Seattle, WA 98195
Site contact: Michael Bailey, PhD · 206-619-2035 · mbailey@uw.edu
Study contacts (from the official record)
- Michael Bailey, PhD · 206-619-2035 · mbailey@uw.edu
- Barbrina Dunmire, MS · mrbean@uw.edu
Similar studies in Washington
All healthy volunteers studies in Washington →- RecruitingHealthy volunteersPhase 1/Phase 2
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
Sanofi
- Location
- Seattle, WA + 49 other US sites
- Eligibility basics
- Ages 60+
- RecruitingHealthy volunteersPhase 1/Phase 2
A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older Adults
GlaxoSmithKline
- Location
- Seattle, WA + 2 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingHealthy volunteersPhase 1/Phase 2
A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age
GlaxoSmithKline
- Location
- Seattle, WA + 5 other US sites
- Eligibility basics
- Ages 18–64
- RecruitingHealthy volunteersPhase 1/Phase 2
Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)
Vega Therapeutics, Inc
- Location
- Seattle, WA + 9 other US sites
- Eligibility basics
- Ages 12–60